Phillips 66 Completes Acquisition of DCP Midstream, LP Common Units
Get Alerts PSX Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.9%
EPS Growth %: +171.4%
Join SI Premium – FREE
HOUSTON & DENVER--(BUSINESS WIRE)-- Phillips 66 (NYSE: PSX) and DCP Midstream, LP (NYSE: DCP) completed the previously announced acquisition by Phillips 66 of all the publicly held common units representing limited partner interests in DCP Midstream for $41.75 per common unit in cash at a total value of approximately $3.8 billion, increasing its economic interest in DCP Midstream to 86.8%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230614491693/en/
Effective with the opening of markets today, DCP Midstream’s common units will no longer be listed on the New York Stock Exchange.
About Phillips 66 and DCP Midstream
Phillips 66 (NYSE: PSX) manufactures, transports and markets products that drive the global economy. The diversified energy company’s portfolio includes Midstream, Chemicals, Refining, and Marketing and Specialties businesses. Headquartered in Houston, Phillips 66 has employees around the globe who are committed to safely and reliably providing energy and improving lives while pursuing a lower-carbon future.
DCP Midstream, LP is a master limited partnership with a diversified portfolio of gathering, processing, logistics and marketing assets.
For more information, visit phillips66.com or follow @Phillips66Co on LinkedIn or Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230614491693/en/
Jeff Dietert (investors)
832-765-2297
[email protected]
Owen Simpson (investors)
832-765-2297
[email protected]
Thaddeus Herrick (media)
855-841-2368
[email protected]
Source: Phillips 66
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tikehau Capital: Disclosure of Shares Repurchases from 05 June 2026 to 11 June 2026
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
- Stem 3 Protocol Now Available for Joint Pain in Atlanta
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Twitter, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share